<DOC>
	<DOCNO>NCT00036894</DOCNO>
	<brief_summary>RATIONALE : CC-5013 may stop growth glioma stop blood flow tumor . PURPOSE : Phase I trial study effectiveness CC-5013 treating patient recurrent glioma .</brief_summary>
	<brief_title>CC-5013 Treating Patients With Recurrent Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose CC-5013 patient recurrent high-grade glioma . - Determine toxic effect drug patient . - Determine pharmacokinetics drug patient . - Determine antiangiogenic activity drug patient . OUTLINE : This dose-escalation study . Patients stratify accord concurrent enzyme-inducing antiepileptic drug ( yes v ) . Patients receive oral CC-5013 weekly 3 week . Treatment repeat every 4 week 12 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos CC-5013 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 2 week . PROJECTED ACCRUAL : A maximum 80 patient ( 40 per stratum ) accrue study within 20 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One following : Histologically confirm highgrade glioma Glioblastoma multiforme Gliosarcoma Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mix oligoastrocytoma Malignant glioma/astrocytoma , otherwise specify Meningioma Hemangioblastoma Ependymoma Primitive neuroectodermal tumor Hemangiopericytoma Progressive glioma Clinically radiographically diagnose brain stem glioma Progressive recurrent disease determine CT scan MRI Biopsy allow prior recent ( i.e. , within past 12 week ) resection recurrent progressive tumor Must fail prior radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : More 8 week Hematopoietic : WBC least 2,300/mm^3 Platelet count least 90,000/mm^3 Hemoglobin least 8 g/dL ( transfusion allow ) Hepatic : Bilirubin le 3 time upper limit normal ( ULN ) SGOT le 3 time ULN No significant active hepatic disease Renal : Creatinine le 2.0 mg/dL OR Creatinine clearance least 60 mL/min No significant active renal disease Cardiovascular : No significant active cardiac disease Other : No malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ cervix No significant active psychiatric disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior interferon No concurrent immunotherapy Chemotherapy : At least 6 week since prior nitrosoureas At least 4 week since prior temozolomide carboplatin At least 3 week since prior procarbazine At least 2 week since prior vincristine At least 4 week since prior cytotoxic chemotherapy No concurrent chemotherapy Endocrine therapy : At least 2 week since prior tamoxifen Concurrent steroid allow control sign symptom increase intracranial pressure stable dose least past 5 day Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics At least 2 week since prior tumor resection Other : At least 2 week since prior noncytotoxic agent Concurrent enzymeinducing antiepileptic drug allow No concurrent rifampin No concurrent grapefruit juice No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2003</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult meningioma</keyword>
	<keyword>adult meningeal hemangiopericytoma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>